Selecting & Developing a Mega Campus

Given the trend towards mega campuses, what are the key factors that pharmaceutical and biotech companies should consider when selecting and developing these facilities?

Most of these companies don't develop these facilities, these mega campuses. These mega campuses are either being built by developers, or they're being repurposed that our old campuses. You know that, that you know we talked about at NEST, that's what we do. That's what we specialize in. These biotech companies and pharmaceutical companies, what they want. They want everything, right? You want a campus that actually supports all strata of the industry, right? You want to have the ability to have to incubate some of these small companies with their, you know, nascent therapies that are promising, you want to have space that you can provide for these companies that are actually outgrowing their incubation space. We call it step out or graduate space.

That space is usually 2,500 feet to maybe 10,000 feet. And then if those companies are ultimately successful, they're going to need space to expand, and that's a postgraduate space. That's a mid-sized company, that's your series, A, B, C, type of venture backed companies that are looking for upwards of 25,000 square feet. But it's also really interesting to have the larger companies and their portfolio companies in these campuses. And again, it creates a ground up ecosystem that you have collaboration across different, you know, sciences. And ultimately, I think in an ideal world, a lot of these tenants want to collaborate with each other and come up with synergies with other tenants to have proximity to other, you know, tenants that are doing, you know, science that could be synergistic with their own science.